London Escorts sunderland escorts 1v1.lol unblocked yohoho 76 https://www.symbaloo.com/mix/yohoho?lang=EN yohoho https://www.symbaloo.com/mix/agariounblockedpvp https://yohoho-io.app/ https://www.symbaloo.com/mix/agariounblockedschool1?lang=EN
Monday, December 2, 2024

Clark Street Value: ESSA Pharma: Another Broken Biotech


ESSA Pharma (EPIX) ($72MM market cap) is the latest addition to the broken biotech basket.  EPIX is a clinical stage pharmaceutical company that was previously focused on developing therapies for the treatment of prostate cancer.  On Thursday (10/31/24), the company announced they were terminating all of their clinical studies and an initiating a review of strategic alternatives.

In the press release the company gave us 9/30 cash numbers:

Liquidity and Outstanding Share Capital

 

· As of September 30, 2024, the Company had available cash reserves and short-term investments of $126.8 million and net working capital of $124.3 million (unaudited figures). The Company has no long-term debt facilities.
· As of September 30, 2024, the Company had 44,388,551 common shares issued and outstanding, and there were 2,920,000 common shares issuable upon the exercise of prefunded warrants at an exercise price of $0.0001.

This one is fairly clean, although we don’t have a severance charge estimate (the company has 50 employees), EPIX hasn’t been burning much cash, only approximately $7MM a quarter prior to the termination of their R&D program.  My back of the envelope math is pretty straight forward, I’m assuming about $20MM of the expenses to wind down the company from here or get it to a place where a reverse merger can be done, feel free to make your own assumptions.

My liquidation value is about 40% higher than where shares traded Friday following the news.

Disclosure: I own shares of EPIX

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles